One Down, But More Remain: PDL Settles Patent Scrap With Alexion Over Soliris
This article was originally published in The Pink Sheet Daily
Executive Summary
One-time $25M payout for license ends dispute over royalties for hemoglobinuria therapy.
You may also be interested in...
PDL Stockholders Get $500 Million, As Promised
Troubled biotech spins off R&D, leaves shell to manage royalty income.
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.
Alexion Biologic Soliris Is First To Get FDA Nod For Rare Blood Disease
Soliris is slated to launch within two weeks from its March 16 approval.